Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07059611 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Not yet
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT07059611 is a Phase 2 study that has not yet begun recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 34 participants.
The verdict
NCT07059611, a Phase 2 study, has not yet begun recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The research study is being conducted to study whether performing injections of a new treatment, called RP2, directly into stomach and esophagus tumors along with standard chemotherapy (called FLOT) is safe and whether it does a better job of killing cancer before surgery compared to chemotherapy alone.
Interventions
- BIOLOGICAL RP2
- COMBINATION_PRODUCT 5-Fluorouracil
- COMBINATION_PRODUCT Leucovorin
- COMBINATION_PRODUCT Oxaliplatin
- COMBINATION_PRODUCT Docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2029-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07059611
The ClinicalTrials.gov registry entry for NCT07059611 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which RP2 is the first listed.
NCT07059611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07059611 about?
NCT07059611 is a clinical study titled "Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma". The research study is being conducted to study whether performing injections of a new treatment, called RP2, directly into stomach and esophagus tumors along with standard chemotherapy (called FLOT) is safe and whether it does a better job of killing cancer before surgery compared to chemotherapy al...
What is the current status of trial NCT07059611?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2026-09-01. Estimated completion is 2029-11-01.
What interventions are being tested in trial NCT07059611?
The interventions under investigation include: RP2 (BIOLOGICAL), 5-Fluorouracil (COMBINATION_PRODUCT), Leucovorin (COMBINATION_PRODUCT), Oxaliplatin (COMBINATION_PRODUCT), Docetaxel (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07059611?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.